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Resistin has been shown to cause insulin resistance and to impair glucose tolerance in rodents, but in humans its physiological role
still remains elusive. The aim of this study was to examine whether resistin mRNA expression in human peripheral mononuclear
cells (PBMCs) and its corresponding plasma levels are altered in type 2 diabetes. Resistin mRNA levels were easily detectable in
humanPBMC,andfoundtobehigherinDM2comparedtohealthywomen(P = .05).Similarly,mononuclearmRNAlevelsofthe
proinﬂammatory cytokines IL-1β,T N F - α, and IL-6 were all signiﬁcantly higher in DM2 compared to control women (P<. 001).
The corresponding plasma resistin levels were slightly, but not signiﬁcantly, increased in DM2 women (P = .051), and overall, they
correlated signiﬁcantly with BMI (r = 0.406, P = .010) and waist circumference (r = 0.516, P = .003), but not with fasting insulin
levelsorHOMA-IR.ResistinmRNAexpressionisincreasedinPBMCfromDM2women,togetherwithincreasedexpressionofthe
inﬂammatory cytokines IL-1β,T N F - α, and IL-6, independent of obesity. These results suggest that resistin and cytokines might
contribute to the low-grade inﬂammation and the increased atherogenic risk observed in these patients.
Copyright © 2008 Panayoula C. Tsiotra et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Resistin and other molecules commonly called adipokines,
such as TNF-α, IL-6, and visfatin, are produced and secreted
by both adipocytes and macrophages, and have been sug-
gested to be important players in the pathogenesis of insulin
resistance and atherosclerosis [1, 2]. Increased production of
these adipokines occurs with expanding obesity, particularly
visceral obesity, by both the adipocytes and the nonfat cells,
mostly macrophages that inﬁltrate the adipose tissue [3, 4].
Indeed, the common origin of macrophages and adipocytes
has been well documented as well as their overlapping
biology and function (accumulation of lipids, expression
and secretion of similar cytokines, such as TNF-α,I L -
6, resistin, visfatin, and expression of genes involved in
lipid metabolism) [4, 5]. Furthermore, recruitment and
accumulation of macrophages in the adipose tissue are
characteristics of obesity [6]. Interestingly, in humans, the
expression of resistin and visfatin is predominantly detected
inthemacrophagespopulatingtheadiposetissue[7].Several
studies have also demonstrated increased expression and
release of the proinﬂammatory cytokines, TNF-α,I L - 1 β,a n d
IL-6, from the adipocytes or the macrophages inﬁltrating the
adipose tissue [3, 7].
Notably, resistin belongs to a family of molecules called
found in inﬂammatory zone (FIZZ), since a member of this
family was found to be expressed in bronchial epithelial
cells during allergic pulmonary inﬂammation in mice [8]. In
human mononuclear cells, where resistin is highly expressed,
its expression is markedly upregulated by lipopolysaccharide
(LPS) and the proinﬂammatory cytokines (Il-6, TNF-α,
and IL-1), acting via the NF-κB-dependent pathway [9].
Furthermore, intravenous administration of endotoxin in
humans markedly increased circulating resistin levels [9,2 Mediators of Inﬂammation
10]. In agreement with these experimental data, patients
with severe inﬂammatory disease have signiﬁcantly higher
serum resistin concentrations, while patients with rheuma-
toid arthritis (RA) show increased resistin levels in their
inﬂamed joints that correlate with markers of inﬂamma-
tion [11]. Furthermore, PPARγ agonists and HMG-CoA
reductase inhibitors (statins), both recognized for their
anti-inﬂammatory properties, decrease macrophage resistin
mRNA and protein secretion, apparently via the NF-κB
pathway [12, 13].
Consistent with the proinﬂammatory nature of resistin,
human resistin powerfully stimulates TNF-α,I L - 1 β,I L -
6, and IL-12 expression in human PBMC and murine
macrophages, an eﬀect that can be abrogated by an NF-
κB inhibitor, indicating the importance of this signalling
pathwayintheresistin-mediatedinﬂammation[14].Resistin
was also shown to increase lipid accumulation in human
macrophages [15]. Resistin also acts on endothelial cells
and promotes their activation, by inducing the expression
and release of monocyte chemoattractant protein (MCP)-
1, endothelin-1 (ET-1), and adhesion molecules, such as
vascular cell adhesion molecule -1 (VCAM-1) and intracel-
lular adhesion molecule-1 (ICAM-1), while at the same time
adiponectin abrogates this eﬀect [16]. Moreover, resistin
is secreted by the macrophages localizing to the athero-
mas, thereby promoting atherosclerosis in humans [17].
Indeed, patients with coronary artery disease (CAD) have
higher serum resistin levels that correlate with markers of
inﬂammation, and are predictive of coronary atherosclerosis
in humans [18, 19]. High serum resistin levels have also
been proposed as predictors of early atherosclerosis in obese
children [20].
While resistin’s role as an inﬂammatory marker in
human’s and rodent’s physiology has been well documented,
its role in obesity and insulin resistance in humans is still
underdebate.Itisimportantthathumanresistinisexpressed
in much higher levels in macrophages than in adipocytes
[21], quite the opposite from the case of mice, in which
resistin clearly impairs insulin sensitivity [22, 23]. Several
human studies have failed to conﬁrm any relationship of
circulating resistin levels with BMI, insulin sensitivity, or
other metabolic parameters [24–26]. However, there have
been reports of increased serum resistin levels in individuals
with obesity and/or type 2 diabetes [27–29].
In the present study, we examined whether resistin TNF-
α, IL-6, and IL-1β mRNA levels from human peripheral
mononuclear cells are altered in type 2 diabetes and whether
they correlate with circulating resistin levels and with indices
of obesity or insulin resistance.
2. SUBJECTS AND METHODS
2.1. Subjects
The study was approved by the “Alexandra” Hospital Ethical
Committee and all subjects gave informed consent. Forty
eight (48) women, all premenopausal, aged between 21 and
49 years, participated in our study. Twenty two had type 2
diabetes (DM2), and twenty six were healthy controls with
normal glucose tolerance (NGT). Both groups were further
divided into two groups: those with BMI < 27 and those with
BMI > 27 (Table 1). All women have had a stable weight, and
they were on a normal eucaloric diet and normal physical
activity,notparticipatinginanyspeciﬁcexerciseprogramfor
thelastthreemonthsprecedingthetest.OftheDM2women,
15 were on diet alone, 4 on oral hypoglycaemic agents, 2 on
insulin, and 1 on combined insulin and oral hypoglycaemic
agents. No DM2 or healthy woman was on thiazolidinedione
or statin medication. All control subjects had no history of
endocrine abnormality and were on no medications.
Body mass index (BMI) was calculated as the ratio
of body weight (Kg) per height (m2). Insulin resistance
was calculated by the homeostasis model assessment index
(HOMA-IR) as [fasting insulin (μU/mL) × fasting glucose
(mmol/L)]/22.5. Insulin sensitivity was calculated by the
Matsuda index as (10000/sqare root of [fasting glucose ×
fasting insulin] × [mean glucose during OGTT × mean
insulin during OGTT]). Fasting glucose, triglycerides, and
free fatty acid (FFA) levels were analyzed on a Falcor 300
Chemical Analyser (Menarini Diagnostics, Italy) and fasting
plasma insulin levels were measured by IRMA (INSI-CTK,
DiaSorin, Italy), in all individuals.
2.2. RNApreparation
Peripheral blood was collected from all women after an
overnight fast and the mononuclear cells were separated
using a Histopaque-1077 gradient (Sigma-Aldrich, USA ).
At the same time, plasma was kept at −80◦Cf o rs u b s e q u e n t
measurement of adipokines.
The mononuclear cells were then left to adhere for 1
hour for the selective isolation of the primary monocyte-
derived macrophages, and total RNA was extracted from
c e l l sa sp r e v i o u s l yd e s c r i b e d[ 30]. Brieﬂy, after the RNA
isolation, cDNA synthesis was performed in all samples
using oligo random primers (NEB, Mass, USA) and MMLV
reverse transcriptase (Promega Corp., Wis , USA) [30]. We
developed a quantitative real-time PCR using ﬂuorescently
labeled hybridization probes to detect resistin and proin-
ﬂammatory (IL-1β,T N F - α, and IL-6) mRNA expression in
human mononuclear cells, in a spectroﬂuorometric thermal
cycler (LightCycler, ROCHE, Mannheim , Germany).
2.3. Primerdesign
Hybridization-speciﬁc primers and hybridization-speciﬁc
probes for all genes were designed and manufactured by the
(TIB MOLBIOL Berlin, Germany). Hybridization primers
and probes for all target and reference genes were showen
in Table 2 .
Primers were chosen to lie between exons whenever
possible and the analysis was performed basically with the
program OLIGO 6.0 (Molecular Biology Insights, Cascade,
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2.4. Quantitativereal-timePCR
Relative quantiﬁcation is the method that determines the
changes in steady-state mRNA levels of a gene across various
samples and expresses them relative to the levels of an
internal reference control gene, usually a housekeeping
gene. In order to quantify resistin, IL-1β,T N F - α,a n dI L -
6 relative mRNA levels, we used the calibrator—normalized
standard curve and the LightCycler Relative Quantiﬁcation
1.0.1 Software (Roche, Mannheim, Germany), as previously
described [30]. Brieﬂy, using this quantiﬁcation method,
results are expressed as the target/reference ratio of the
sample divided by the target/reference ratio of the calibrator,
and it does not require a standard curve in each run
(Roche Applied Science, Technical Note No. LC 13/2001-
Relative Quantiﬁcation). The human housekeeping genes
of β-actin and porphobilinogen deaminase (PBGD) were
used as standards for normalization. Selection of either β-
actin or PBGD as housekeeping genes was necessary because
the copy number of the housekeeping gene should be
in a similar range with that of the target gene to make
comparative quantiﬁcation possible (Roche Applied Science,
Technical Note No. LC 15/2002-Selection of Housekeeping
Genes). Thus, the PBGD house keeping gene was chosen
for the relative quantiﬁcation of the IL-6 mRNA expression
because of the very low level of IL-6 expression in the
calibrator (HL60 induced with phorbol myristyl acetate
(PMA)) mRNA.
Standard curves describing the PCR eﬃciencies of the
target (resistin, IL-1β,T N F - α, or IL-6) and the reference
genes (β-actin or PBGD) were created from a dilution
series of the calibrator cDNA, using the Second derivative
maximum method with the arithmetic baseline adjustment.
The second derivative maximum method was used for the
determination of the various crossing points (Cps) of the
target and the reference gene in each sample. Finally, a cor-
responding coeﬃcient ﬁle was created, which determines the
eﬃciencyforthetargetandthe referencegene.Ampliﬁcation
of each sample was performed in triplicate, in diﬀerent runs,
and ﬂuorescence resulting from the close proximity of the
annealed hybridization probes was detected at the end of the
annealing step of each PCR cycle.
The results from diﬀerent PCR runs were run randomly
in ethidium bromide-stained agarose gels and photographed
in an Image Analyser VDS System (Amersham-Pharmacia
Biotech, Sweden) .
Immunoassays
Circulating levels of resistin (BioVender, Canal zone, USA
), TNF-α(R&D Systems, UK), and IL-6 (R&D Systems,
UK) were measured in the plasma of all women, using
standard commercial enzyme-linked immunosorbent assays
according to the manufacturers’-recommended protocols.
IL-1β circulating protein levels were measured in the plasma
of all women, using a high sensitivity multiplex assay (xMAP
technology) and the ﬂuorescently labeled microsphere beads
(Linco-Millipore Corp., USA) , in a LUMINEX 200 instru-
ment (Luminex Corp., USA) . We could not detect IL-1β in
the majority of our subjects (in 57% of controls and 55% of
DM2), making the analysis of circulating IL-1β problematic.
The sensitivities of the assays were 0.2ng/mL (resistin),
0.12pg/mL (TNF-α), <0.094pg/mL (IL-6), 0.06pg/mL (IL-
1β), the intra- and the interassay coeﬃcients of variation
were, respectively, 3.6% and 6.7% (resistin), 6.6% and 13.4%
(TNF-α), 6.9% and 14.1% (IL-6), 3.11% and 2.16% (IL-1β).
All samples were measured in duplicate.
2.5. Statisticalanalysis
Statistical analysis was performed using the SPSS version
14.0.1 software (Chicago, Ill, USA). Data are expressed as
mean ±SEMofn-independentexperiments.Nonparametric
statistical analyses were applied (Spearman’s correlation test
and nonparametric Mann-Whitney test), where appropriate.
A P-value of less than .05 was considered statistically
signiﬁcant.
3. RESULTS
3.1. Clinicalcharacteristicsofstudysubjects
Table 1 shows the clinical characteristics of the DM2 and
healthy NGT women, who were further divided into two
subgroups according to their BMI, one with BMI < 27 and
one with BMI > 27. The groups were generally well matched
between them. DM2 women, however, had signiﬁcantly
higher waist circumference, triglyceride and FFA levels, and
lower HDL cholesterol levels compared to the BMI-matched
controls.
Resistin, TNF-α,I L - 6 ,I L - 1 β mRNA expression from
human mononuclear-monocytic cells is elevated in DM2
women.
Resistin mRNA expression was easily detected in human
mononuclear-monocytic cells in both DM2 and NGT
women, and was signiﬁcantly higher (0.57 ± 0.1v e r s u s
0.52 ± 0.1 arbitrary units, P = .05) in the former group
(Figure 1(a)), while no signiﬁcant diﬀerences were observed
between the two BMI subgroups (Table 3).
TNF-α,I L - 6m R N Aa n dI L - 1 β mRNA levels were
signiﬁcantly higher (∼10-, 15-, and 10-fold, resp.) in DM2
women compared to NGT women [0.34 ± 0.1v e r s u s0 .03 ±
0.01 (P<. 001), 342.98 ± 127.9v e r s u s2 1 .64 ± 12.6( P<
.001), and 139.36 ± 40.2v e r s u s1 3 .21 ± 7.8 arbitrary units
(P = .001), resp.] (Figures 1(b), 1(c), and 1(d)).
ResistinmRNAlevelscorrelatedpositivelywithmononu-
clear IL-1β,a n dT N F - α,m R N Al e v e l s( r = 0.324, P<
.05 and r = 0.447, P<. 01, resp.). Furthermore, TNF-α
and IL-6 mRNA levels correlated positively between them
(r = 0.687, P<. 001) and also each one of them with
the IL-1β mRNA levels (r = 0.767, P<. 001 and r =
0.765, P<. 001, resp.), the 2-hour OGTT glucose levels
(r = 0.462, P = .005 and r = 0.486, P = .004, resp.) and
negatively with HDL cholesterol levels (r =− 0.367, P<. 02
and r =− 0.372, P<. 02, resp.), while IL-1β mRNA levels
correlated positively with BMI (r = 0.374, P = .017), waist
circumference (r = 0.414, P = .019), fasting glucose levels
(r = 0.365, P = .022), HOMA-IR (r = 0.325, P = .043),4 Mediators of Inﬂammation
Table 1:Patients’characteristics,theirfastingglucose,fastinginsulin,triglycerides,HDLandFFAlevels,theHOMA-IRandMatsudaindices.
n BMI
(Kg/m2)
Waist
(cm)
Fasting
glucose
(mg/dL)
Fasting
insulin
(μU/mL)
HOMA-IR Matsuda Triglycerides
(mg/dL)
HDL
(mg/dL)
FFA
(mmol/L)
NGT BMI < 27 14 22.5 ±0.7 76.5 ±
2.3 87.5 ±3.66 .4 ±0.6 1.4 ±0.19 .3 ±0.9 63.2 ±5.04 6 .5 ±3.40 .43 ±0.05
BMI > 27 12 32.9 ±1.5
∗ 95.7 ±
3.0
∗ 98.3 ±2.1
∗ 12.7 ±2.1
∗ 3.0 ±0.5
∗ 5.0 ±1.3
∗ 100.2 ±18.94 4 .0 ±3.30 .47 ±0.05
DM2 BMI < 27 8 23.7 ±0.7
§ 78.2 ±
3.4
§ 156.9 ±32.9
∗§ 8.3 ±1.9 4.2 ±2.16 .3 ±1.4 80.3 ±17.43 9 .0 ±2.90 .55 ±0.10
BMI > 27 14 36.4 ±1.4
∗ 108.1 ±
3.0
∗§ 136.7 ±13.0
∗§ 16.6 ±2.6
∗ 5.6 ±1.0
∗ 2.4 ±0.3
∗§ 150.8 ±26.5
∗ 27.4 ±1.5
∗§ 0.59 ±0.04
∗
Mean ± SEM: ∗P<. 03 versus NGT-BMI < 27; §P<. 05 versus NGT-BMI > 27.
Table 2
5 -sense primer-3  5 -a-sense primer-3 
Resistin GGGCTGTTGGTGTCTAGCAAG GTCTCGGCGCGCACAT
IL-1β CAGGGACAGGATATGGAGCAA GCAGACTCAAATTCCAGCTTGTTA
TNF-α ACAAGCCTGTAGCCATGTT AAAGTAGACCTGCCCAGACT
IL-6 CCAATCTGGATTCAATGAGGAGACT GAGCCCTCAGGCTGGACTG
β-actin CTTCTACAATGAGCTGCGTGTG GTGAGGATCTTCATGAGGTAGTCAGTC
PBGD GGCTGCAACGGCGGAA CCTGTGGTGGACATAGCAATGATT
5 -FL probe-3  5 -LC Red640/LCRed705 probe-3 
Resistin GCGACCTCCTGGATCCTCTCATTGA GCTTCTTCCATGGAGCACAGGGTC
IL-1β GCTTATCATCTTTCAACACGCAGGACA GTACAGATTCTTTTCCTTGAGGCCCA
TNF-α GCATTGGCCCGGCGGTTC CCACTGGAGCTGCCCCTCAGCT
IL-6 AGATGCAATAACCACCCCTGACCCAA CACAAATGCCAGCCTGCTGACGAA
β-actin GGTATGCCCTCCCCCATGCC TCCTGCGTCTGGACCTGGCTG
PBGD CATACAGACGGACAGTGTGGTGGCAAC TGAAAGCCTCGTACCCTGGCCTG
glycosylated hemoglobin (r = 0.542, P = .001), FFA levels
(r = 0.335, P = .043), and negatively with HDL cholesterol
levels (r =− 0.395, P = .015).
3.2. Circulatingresistin,TNF-α,IL-6,andIL-1β
proteinlevels
Plasma resistin levels tended to be overallsigniﬁcantly higher
in DM2 women compared to NGT control women (P =
.051) (Figure 2), but no signiﬁcant diﬀerences were observed
between the two BMI subgroups. Circulating TNF-α,I L - 6 ,
and IL-1β protein levels did not diﬀerentiate between the
DM2 and the NGT-control women (Figure 2), although in
the subgroup of DM2 with BMI > 27, TNF-α and IL-6
plasma levels were signiﬁcantly higher compared to NGT
women (Table 4).
Circulating resistin correlated positively with mononu-
clear resistin, IL-6 and IL-1β mRNA expression (r =
0.526, P = .001 and r = 0.354, P = .029 and r =
0.425, P = .009, resp.), BMI and waist circumference (r =
0.406, P = .010 and r = 0.516, P = .003), but not with
HOMA-IR, fasting insulin, or glucose plasma levels. TNF-α
and IL-6 plasma levels also correlated with BMI and waist
circumference (r = 0.361, P = .013 and r = 0.651, P<
.001 and r = 0.379, P = .023 and r = 0.676, P<. 001,
resp.) as well as with fasting glucose, insulin and triglyceride
levels, the HOMA-IR, while they correlated negatively with
the Matsuda index and HDL cholesterol levels.
4. DISCUSSION
We have demonstrated that resistin mRNA expression from
human peripheral monocyte-enriched mononuclear cells is
elevated in type 2 diabetic women, compared to healthy
control women, in parallel with signiﬁcant increases in
mononuclear IL-1β,T N F - α, and IL-6 mRNA expression.
Resistin, a 12.5-kDa cysteine-rich adipokine, which was
shown to cause insulin resistance and to impair glucose
tolerance in rodents [1], is also highly expressed in human
mononuclear cells and macrophages [21]. While in rodents,
adipocyte-produced resistin is mainly involved in glucose
metabolism and insulin resistance: in humans, monocyte-
produced resistin seems to have potent proinﬂammatory
properties. Various inﬂammatory stimuli could result in
hyperresistinemia in humans [9, 10], while human resistin
can stimulate the expression of the inﬂammatory cytokines
TNF-α and IL-6 in both human and murine macrophages,
via an NF-κB-dependent pathway [11, 14]. The proinﬂam-
matory nature of resistin was further documented by the
ﬁndings that serum resistin concentrations were signiﬁcantlyPanayoula C. Tsiotra et al. 5
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Figure 1: (a) Bar graphs compare relative resistin/β-actin mRNA levels, (b) TNF-α/β-actin mRNA levels, (c) IL-6/PBGD mRNA levels, and
(d) IL-1β/β-actin mRNA levels, from peripheral mononuclear-enriched monocytes from NGT-control and DM2 women. ∗P<. 05 versus
NGT-women.
Table 3: Relative resistin, TNF-α, IL-6, and IL-1β mRNA levels from mononuclear cells between the subgroups of the NGT- and the DM2-
women.
Resistin/β-actin TNF-α/β-actin IL-6/PBGD IL-1β/β-actin
NGT BMI < 27 0.50 ±0.14 0.03 ±0.008 20.1 ±16.15 .4 ±1.7
BMI > 27 0.54 ±0.26 0.03 ±0.01 23.5 ±20.72 3 .1 ±17.6
DM2 BMI < 27 0.70 ±0.25 0.31 ±0.16
∗§ 242.0 ±120.5
∗§ 79.9 ±44.0
BMI > 27 0.48 ±0.07 0.37 ±0.16
∗§ 405.1 ±194.9
∗§ 169.1 ±55.1
∗§
Data expressed as mean ± SE: ∗P<. 017 versus NGT-(BMI < 27)-women; §P<. 013 versus NGT-(BMI > 27)-women.
elevated in patients with severe inﬂammatory disease and
in patients with previous myocardial infarction, in whom
they positively correlated with markers of inﬂammation,
independent of CRP [11, 18–20].
In the present study, we have demonstrated that resistin
mRNA levels from human peripheral monocyte-enriched
mononuclear cells were higher in the DM2 compared to
healthy women, which was independent of BMI. It should
be noted that the diﬀerence did not reach signiﬁcance
between the individuals groups, but only when all patients
were grouped together in NGT and DM2. This is obvi-
ously due to the small number of individuals used in
our study, which is a weakness of our data. The above
overall diﬀerence may suggest that, unlike inﬂammatory
cytokine mRNA expression from human mononuclear cells,
mononuclear resistin mRNA is not appreciably increased
in vivo with chronic hyperinsulinemia that characterizes
obesity. In support of this, in vitro studies demonstrated that
insulin decreases resistin mRNA from human monocytes
[31], while in the 3T3-L1 adipocytes, insulin downregulated
resistin mRNA and protein secretion—possibly through
the PI 3-kinase, ERK, or p38 MAP-kinase pathways—[32].
Recently, however, another study demonstrated that acute
hyperinsulinemia is associated withincreased resistin mRNA
expression in human subcutaneous adipose tissue and a
similar increase in plasma resistin levels [33].6 Mediators of Inﬂammation
Table 4: Circulating resistin, TNF-α, IL-6, and IL-1β protein levels between the subgroups of the NGT- and the DM2-women.
Resistin (ng/mL) TNF-α (pg/mL) IL-6 (pg/mL) IL-1β (pg/mL)
NGT BMI < 27 2.65 ±0.19 2.07 ±0.19 0.80 ±0.14 1.37 ±0.39
BMI > 27 2.98 ±0.23 2.32 ±0.20 1.77 ±0.36
∗ 0.97 ±0.52
DM2 BMI < 27 3.24 ±0.45 2.14 ±0.45 0.93 ±0.18
§ 1.19 ±0.85
BMI > 27 3.36 ±0.29 3.24 ±0.36
∗ 1.84 ±0.28
∗ 0.79 ±0.42
Data expressed as mean ± SE: ∗P<. 015 versus NGT-(BMI < 27)-women; §P<. 05 versus NGT-(BMI > 27)-women.
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Figure 2: Comparison of circulating resistin, TNF-α,I L - 6 ,a n d
IL-1β protein levels between the NGT-healthy control and DM2
women. ∗P<. 051 versus NGT-women.
Macrophages and adipocytes share an overlapping biol-
ogy and function [4], and inﬁltration of the adipose tissue
with the macrophages is characteristic of obesity [6]. Several
recent studies suggest that obesity is associated with an
increase in adipose tissue macrophages, which also partic-
ipate in the inﬂammatory process through the elaboration
of cytokines [3, 4, 34]. Proinﬂammatory cytokines (TNF-α
and IL-6) and adipokines (resistin and visfatin), produced
by the peripheral macrophages, can also be expressed in
increased amounts in the fat tissue of obese individuals
acting in parallel as important regulators of inﬂammation,
atherosclerosis, and insulin sensitivity in both tissues. In
a recent study, the expression of two adipokines, resistin,
and visfatin was detected predominantly in the macrophages
populating the human visceral fat tissue, suggesting that
these adipokines might have an important role in the
inﬂammatory load of obesity [7].
The putative role of resistin in obesity-induced insulin
resistance was conﬁrmed by studies, in rodents, demon-
strating that administration of recombinant resistin impairs
hepatic insulin sensitivity and glucose metabolism [22],
while possibly playing a role in maintaining fasting blood
g l u c o s el e v e l s[ 23]. This was debated by various human
studies demonstrating that there is no relationship of
circulating resistin levels with BMI, insulin sensitivity, or
other metabolic parameters [24–26]. However, other studies
found increased serum resistin levels in individuals with
obesityand/ortype2diabetes[27–29].Theaboveconﬂicting
data lead to the ascertainment that despite the initial belief
that resistin could be the factor linking obesity and type
2 diabetes, its biologic signiﬁcance in the pathogenesis of
insulin resistance, at least in humans, is under controversy
[35].Infact,whileinrodentsadiposetissueistheonlysource
of resistin production, in humans resistin is barely detectable
in adipocytes, and actual resistin mRNA levels are much
higher in monocytes and macrophages than in adipocytes
[21].
In the present study, we have additionally demonstrated
that plasma resistin levels are marginally increased in type
2 diabetic women compared to healthy women, and this
increase was detected in both subgroups, those with BMI <
27 and those with BMI > 27. Thus, our data are inline with
previous reports that found elevated serum resistin levels in
type 2 diabetic subjects compared with nondiabetic subjects
[28, 29, 36]. Nevertheless, we observed no correlation of cir-
culating resistin with insulin resistance indices. However, the
observed positive correlation of circulating resistin with BMI
and waist circumference might support some association of
resistin with obesity-induced insulin resistance. Therefore,
the observed increased plasma resistin levels in the DM2
women could be due to the increased visceral obesity, as
it reveals the higher waist circumference of these patients.
Circulating Il-1β did not diﬀerentiate between the healthy
controlandtheDM2women,aresultthatlineswithprevious
studies in which Il-1β alone cannot associate with the risk of
developing type 2 diabetes, while Il-1β was even decreased
in an impaired glucose tolerance (IGT) group compared to
NGT subjects [37, 38]. It should be emphasized that due to
the large number of subjects in whom plasma IL-1β levels
were undetectable, they should be interpreted with caution.
TNF-α and IL-6 plasma levels were also similar between the
NGT and the DM2womenofour study, although theirlevels
are signiﬁcantly increased in the subgroup of DM2 women
with BMI > 27, compared to NGT with BMI < 27 women;
moreover, they were signiﬁcantly correlated with the obesity
and insulin resistance indices. While in the EPIC-Potsdam
study the elevated levels of TNF-α and IL-6 were found to be
strongly associated with future type 2 diabetes, other studies
failed to demonstrate increased TNF-α and IL-6 plasma
levels in DM2 patients [37, 39]. The above discrepancy could
be due to the small number of subjects used in the later
study, as it was also in our case, and due to ethnic diﬀerences
between the various studies.
Obesity-induced insulin resistance is characterized by
a chronic, systemic low-grade state of inﬂammation and
is strongly associated with inﬂammatory markers, while
inﬂammation may contribute to insulin resistance and
atherosclerosis [2, 5, 40]. Therefore, with expanding obesityPanayoula C. Tsiotra et al. 7
and increased macrophage inﬁltration of the adipose tissue,
there is an increased cytokine production by both cell pop-
ulations, with all the detrimental metabolic consequences
on insulin resistance and on the inﬂammatory status [4,
6, 41]. In the present study, we have demonstrated that
in type 2 diabetes, there is an increased mRNA expression
of resistin, along with signiﬁcant increases in TNF-α,I L - 6 ,
and Il-1β mRNA expression by the peripheral circulating
mononuclear cells. The results from this study, together
with previous data, showing higher mononuclear visfatin
mRNA expression in the DM2 women [30], suggest that
an overload of mRNA expression of inﬂammatory cytokines
and adipokines occurs in the mononuclear cells from type
2 diabetic patients, aggravating the proinﬂammatory status
of this condition. These data further support the notion that
the peripheral circulating mononuclear cells can indeed be
an important source of resistin production in humans. Thus,
in type 2 diabetes, macrophages that inﬁltrate the stroma
of the adipose tissue and/or the vascular endothelium can
locally produce and secrete increased resistin and cytokine
(Il-1β,T N F - α, and IL-6) levels, which may enhance the
inﬂammatory load and the associated insulin resistance and
vascular dysfunction observed in these patients.
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